Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
Background: Oncotype-Dx (ODx) is a 21-gene assay used as a prognostic and predictive tool for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, node-negative, or 1 to 3 lymph node-positive early breast cancers (EBCs). The cost of the test, which is not avai...
| Publicado en: | Breast Cancer: Basic & Clinical Research pp. 1 - 13 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | pictorial research systematic review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
5/21/2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=177391407&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 177391407 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11782234 B078 jtl: Breast Cancer: Basic & Clinical Research issn: 11782234 maglogo: Y pubinfo: dt: 5/21/2024 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 177391407 177391407 177391407 10.1177/11782234241255211 177391407 ppf: 1 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature. aug: au: Mooghal, Mehwish Khan, Muhammad Ali Akbar Samar, Mirza Rameez Shaikh, Hafsa Valimohammad, Azmina Tajdin Idrees, Romana Abdul Rashid, Yasmin Sattar, Abida K affil: Section of Breast Surgery, Department of Surgery, The Aga Khan University Hospital, Karachi, Pakistan sug: subj: Tumor Markers, Biological Analysis Neoplasm Recurrence, Local Risk Factors Hormone Receptor Positive Breast Neoplasms Risk Assessment Decision Making, Clinical Human Systematic Review PubMed Embase Low and Middle Income Countries Chi Square Test Fisher's Exact Test Data Analysis Software Checklists Chemotherapy, Adjuvant Machine Learning Artificial Intelligence Cost Effectiveness Analysis Resource-Limited Settings Health Resource Allocation Individualized Medicine Epidermal Growth Factor Receptors ab: Background: Oncotype-Dx (ODx) is a 21-gene assay used as a prognostic and predictive tool for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, node-negative, or 1 to 3 lymph node-positive early breast cancers (EBCs). The cost of the test, which is not available in low-middle income countries (LMICs), is not within the means of most individuals. The Ki-67 index is a marker of tumor proliferation that is cost-effective and easily performed and has been substituted in many cases to obtain prognostic information. Objective: We aimed to identify the correlation between the ODx recurrence score (RS) and the Ki-67 index in HR-positive EBCs and to determine whether Ki-67, like the ODx, can help facilitate clinical decision-making. Design: Systematic review correlating Ki-67 index and ODx in HR-positive and HER2-negative EBCs as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data sources and methods: We searched different databases between January 2010 and May 2023 and included retrospective/prospective cohorts, clinical trials, case-control, and cross-sectional studies involving HR-positive and HER2-negative EBCs correlating the Ki-67 index and ODx RS categories. Results: Of the 18 studies included, 16 indicated a positive or weakly positive correlation between ODx and the Ki-67 index. The combined P value of the included studies is <0.05 (P =.000), which shows a statistical significance between the 2. Our review also discusses the potential of machine learning and artificial intelligence (AI) in Ki-67 assessment, offering a cost-effective and reproducible alternative. Conclusion: Even although there are limitations, studies indicate a favorable association between ODx and the Ki-67 index in specific situations. This implies that Ki-67 can offer important predictive details, especially regarding the likelihood of relapse in HR-positive EBC. This is particularly significant in LMICs where financial constraints often hinder the availability of costly diagnostic tests. Plain Language Summary: Comparing Ki-67 and Oncotype-Dx Tests for Predicting Early Breast Cancer Outcomes: A Comprehensive Review The study explored the correlation between the expensive Oncotype-Dx (ODx) test and the more affordable Ki-67 index in predicting outcomes for certain breast cancers. Results from 16 out of 18 studies indicated a significant link between the 2 tests, suggesting Ki-67 could be a cost-effective alternative, especially in low- to middle-income countries. pubtype: Academic Journal doctype: pictorial research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|